Regeneron Pharmaceuticals Inc
REGN Real Time Price USDRecent trades of REGN by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by REGN's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$30,000 Jul 11, 2025 Issue: Taxation/Internal Revenue Code
-
$50,000 Jul 01, 2025 Issue: Budget/Appropriations
-
$400,000 Apr 21, 2025 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid Copyright/Patent/Trademark Trade (domestic/foreign)
-
$400,000 Jan 21, 2025 Issue: Health Issues Medicare/Medicaid Copyright/Patent/Trademark
-
$400,000 Oct 21, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$400,000 Jul 22, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$430,000 Apr 22, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$430,000 Jan 22, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$400,000 Oct 20, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$370,000 Jul 20, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$320,000 Jan 20, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$320,000 Oct 20, 2022 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$340,000 Jul 20, 2022 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$370,000 Apr 20, 2022 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$370,000 Jan 20, 2022 Issue: None
-
$360,000 Oct 20, 2021 Issue: None
-
$310,000 Jul 20, 2021 Issue: None
-
$330,000 Apr 20, 2021 Issue: None
-
$330,000 Jan 21, 2021 Issue: None
-
$480,000 Oct 20, 2020 Issue: None
-
$320,000 Jul 20, 2020 Issue: None
-
$370,000 Apr 20, 2020 Issue: None
-
$340,000 Jan 21, 2020 Issue: None
-
$180,000 Oct 21, 2019 Issue: Health Issues Medicare/Medicaid Copyright/Patent/Trademark
-
$250,000 Jul 22, 2019 Issue: Taxation/Internal Revenue Code Copyright/Patent/Trademark Health Issues Medicare/Medicaid
-
$300,000 Apr 22, 2019 Issue: Copyright/Patent/Trademark Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$90,000 Jan 22, 2019 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Copyright/Patent/Trademark
-
$180,000 Oct 22, 2018 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$190,000 Jul 20, 2018 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
-
$200,000 Apr 20, 2018 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$260,000 Jan 22, 2018 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
-
$120,000 Oct 20, 2017 Issue: Medicare/Medicaid Budget/Appropriations Taxation/Internal Revenue Code Health Issues
-
$120,000 Jul 20, 2017 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid Budget/Appropriations
-
$240,000 Apr 20, 2017 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
-
$130,000 Jan 20, 2017 Issue: Health Issues Medicare/Medicaid
-
$130,000 Oct 20, 2016 Issue: Health Issues
-
$120,000 Jul 20, 2016 Issue: Health Issues
-
$50,000 Apr 19, 2016 Issue: Health Issues
-
$50,000 Jan 16, 2016 Issue: Health Issues
-
$50,000 Oct 20, 2015 Issue: Health Issues
-
$50,000 Jul 20, 2015 Issue: Health Issues
-
$60,000 Apr 20, 2015 Issue: Health Issues
-
$52,000 Jan 19, 2015 Issue: Health Issues
-
$50,000 Oct 20, 2014 Issue: Health Issues
-
$50,000 Jul 21, 2014 Issue: Health Issues
-
$50,000 Jan 22, 2014 Issue: Health Issues
-
$50,000 Oct 21, 2013 Issue: Health Issues
-
$40,000 Jul 22, 2013 Issue: Health Issues
-
$30,000 Apr 24, 2013 Issue: Health Issues
-
$30,000 Feb 02, 2013 Issue: Health Issues
-
$30,000 Oct 31, 2012 Issue: Health Issues
Estimated quarterly lobbying spending
REGN Revenue by Segment or Geography
New patents grants
-
Patent Title: Anti-pcsk9 antibodies Apr. 08, 2025
-
Patent Title: Human antibodies to the human glucagon receptor (hgcgr) and methods of use thereof to lower blood glucose or ketone levels Apr. 08, 2025
-
Patent Title: Use of a vegf antagonist to treat angiogenic eye disorders Apr. 08, 2025
-
Patent Title: Genome-based methods for reducing cardiovascular risk Apr. 01, 2025
-
Patent Title: Tcra homing endonuclease variants Apr. 01, 2025
-
Patent Title: High confidence compound identification by liquid chromatography-mass spectrometry Mar. 25, 2025
-
Patent Title: Microchip capillary electrophoresis assays and reagents Mar. 25, 2025
-
Patent Title: Kelch domain containing 7b (klhdc7b) variants and uses thereof Mar. 25, 2025
-
Patent Title: Methods and compositions for therapeutic protein delivery Mar. 25, 2025
-
Patent Title: Nucleic acid molecules encoding bispecific anti-bcma x anti-cd3 antibodies Mar. 25, 2025
-
Patent Title: Humanized dipeptidyl-peptidase iv (dpp4) animals Mar. 25, 2025
-
Patent Title: Data pipeline Mar. 18, 2025
-
Patent Title: Microchip capillary electrophoresis assays and reagents Mar. 18, 2025
-
Patent Title: Anti-cd63 antibodies, conjugates, and uses thereof Mar. 18, 2025
-
Patent Title: Human antibodies to fel d1 and methods of use thereof Mar. 18, 2025
-
Patent Title: Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments Mar. 18, 2025
-
Patent Title: Genetically modified mouse with a humanized pnpla3 gene and methods of use Mar. 18, 2025
-
Patent Title: Protein a chromatography-electrospray ionization mass spectrometer Mar. 11, 2025
-
Patent Title: Systems and methods for chromatography use and regeneration Mar. 11, 2025
-
Patent Title: N-terminal scfv multispecific binding molecules Mar. 04, 2025
-
Patent Title: N-terminal scfv multispecific binding molecules Mar. 04, 2025
-
Patent Title: Online chromatography and electrospray ionization mass spectrometer Mar. 04, 2025
-
Patent Title: Sustained release formulations using non-aqueous membrane emulsification Mar. 04, 2025
-
Patent Title: Humanized il-6 and il-6 receptor Mar. 04, 2025
-
Patent Title: Eukaryotic cells comprising adenovirus-associated virus polynucleotides Feb. 25, 2025
-
Patent Title: Methods of treating decreased bone mineral density with cluster of differentiation 109 (cd109) inhibitors Feb. 25, 2025
-
Patent Title: Hydrophobic interaction chromatography for viral clearance Feb. 25, 2025
-
Patent Title: Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden Feb. 18, 2025
-
Patent Title: Cblb endonuclease variants, compositions, and methods of use Feb. 18, 2025
-
Patent Title: Systems and methods for producing a mixer Feb. 18, 2025
-
Patent Title: Auto-injector and related methods of use Feb. 18, 2025
-
Patent Title: Auto-injector and related methods of use Feb. 18, 2025
-
Patent Title: Taurine supplemented cell culture medium and methods of use Feb. 11, 2025
-
Patent Title: Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (ido1) Feb. 04, 2025
-
Patent Title: Treatment of liver disease with mitochondrial glycerol-3-phosphate acyltransferase (gpam) inhibitors Feb. 04, 2025
-
Patent Title: Antigen binding molecule formats Feb. 04, 2025
-
Patent Title: Compositions and methods for internalizing enzymes Feb. 04, 2025
-
Patent Title: Igg fc-il2-rα-il2 fusions and methods of use thereof Feb. 04, 2025
-
Patent Title: Crispr/cas screening platform to identify genetic modifiers of tau seeding or aggregation Jan. 28, 2025
-
Patent Title: Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists Jan. 28, 2025
-
Patent Title: Adam6 mice Jan. 28, 2025
-
Patent Title: Anti-vegf protein compositions and methods for producing the same Jan. 21, 2025
-
Patent Title: Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein Jan. 21, 2025
-
Patent Title: Non-human animals comprising a humanized coagulation factor 12 locus Jan. 21, 2025
-
Patent Title: Use of lc-ms/ms to quantitate protein biomarkers Jan. 14, 2025
-
Patent Title: Retainer adapter assembly Jan. 14, 2025
-
Patent Title: Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer Jan. 07, 2025
-
Patent Title: Il10 agonists and methods of use thereof Jan. 07, 2025
-
Patent Title: Methods of treating skin cancer with histidine ammonia-lyase (hal) agonists Jan. 07, 2025
-
Patent Title: Antigen binding molecule formats Dec. 31, 2024
Federal grants, loans, and purchases
- $494,095 2021-11-24 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $0 2021-09-29 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $148,229 2021-09-08 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $0 2021-04-07 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $2,625,000,000 2021-01-12 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
Estimated quarterly amount awarded from public contracts
Recent insights relating to REGN
Recent picks made for REGN stock on CNBC
ETFs with the largest estimated holdings in REGN
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $REGN stock a Buy, Sell, or Hold?
- What is the price target for $REGN stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $REGN stock?
- Who owns the most shares of $REGN stock?
- What funds own $REGN stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view REGN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.